HomeCompareCSAMF vs PFE

CSAMF vs PFE: Dividend Comparison 2026

CSAMF yields 9.90% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSAMF wins by $407896.06M in total portfolio value
10 years
CSAMF
CSAMF
● Live price
9.90%
Share price
$4.82
Annual div
$0.48
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$407896.11M
Annual income
$400,131,239,290.63
Full CSAMF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — CSAMF vs PFE

📍 CSAMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSAMFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSAMF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSAMF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSAMF
Annual income on $10K today (after 15% tax)
$841.44/yr
After 10yr DRIP, annual income (after tax)
$340,111,553,397.04/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, CSAMF beats the other by $340,111,530,268.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSAMF + PFE for your $10,000?

CSAMF: 50%PFE: 50%
100% PFE50/50100% CSAMF
Portfolio after 10yr
$203948.08M
Annual income
$200,065,633,250.59/yr
Blended yield
98.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CSAMF
No analyst data
Altman Z
1.1
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSAMF buys
0
PFE buys
0
No recent congressional trades found for CSAMF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSAMFPFE
Forward yield9.90%6.20%
Annual dividend / share$0.48$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$407896.11M$51.1K
Annual income after 10y$400,131,239,290.63$27,210.54
Total dividends collected$407370.38M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CSAMF vs PFE ($10,000, DRIP)

YearCSAMF PortfolioCSAMF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$12,680$1,979.87$9,161$701.38+$3.5KCSAMF
2$18,260$4,692.42$8,610$859.79+$9.7KCSAMF
3$32,169$12,630.66$8,366$1,081.25+$23.8KCSAMF
4$76,012$41,591.87$8,483$1,405.66+$67.5KCSAMF
5$265,032$183,698.34$9,084$1,907.24+$255.9KCSAMF
6$1,480,778$1,197,194.33$10,418$2,732.78+$1.47MCSAMF
7$14,087,114$12,502,681.79$13,007$4,193.56+$14.07MCSAMF
8$237,394,699$222,321,486.64$18,010$7,005.87+$237.38MCSAMF
9$7,256,891,462$7,002,879,134.27$28,216$12,979.89+$7256.86MCSAMF
10$407,896,113,155$400,131,239,290.63$51,081$27,210.54+$407896.06MCSAMF

CSAMF vs PFE: Complete Analysis 2026

CSAMFStock

CSAM Health Group AS provides various ehealth solutions in Norway and internationally. The company offers CSAM Arcidis, an integrated system for teleradiology; CSAM DICOM Server for handling radiology data; CSAM HelseMail for transfer of confidential patient data between healthcare organizations; CSAM Infobroker, a vendor-neutral telemedicine system for radiology that enables multiple clinicians to share resources and knowledge; CSAM S7, a platform for self-care and health counselling; CSAM Web Client, a web-based user interface and connectivity solution that allows users to access multiple CSAM applications and functions; and CSAM XDS, a central archive for storing and managing various types of clinical patient data. It also provides CSAM Cardio, an ECG and diagnostic storage tool; CSAM CIMA, a mobile application for capturing, using, and sending medical media; CSAM Media, a web-based medical imaging solution; CSAM Medimaker for image management and workflow solution; CSAM Picsara, an image management solution; and CSAM TRIS, a radiology information system. In addition, the company offers CSAM Partus, a maternity information system; CSAM Natus, a maternity care system; CSAM iPana Labor Information System, a web-based labour information system; CSAM iPana Maternity, a cloud-based service platform that enables expectant mothers, hospitals, and maternity clinics to electronically collect, store, and share medical information; and CSAM Fertsoft, a care and practice management software. Further, it provides CSAM Optima Predict solution for operational planning; CSAM Optima Live; CSAM AMIS, an emergency medical information system; CSAM IMTS, a tool for assessing and prioritizing patients; CSAM Paratus, an emergency response system; CSAM CoordCom; CSAM ResQMobile; CSAM Cytodose, an oncology management solution; and CSAM ProSang, an advanced laboratory information management system. The company was founded in 1999 and is headquartered in Oslo, Norway.

Full CSAMF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CSAMF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSAMF vs SCHDCSAMF vs JEPICSAMF vs OCSAMF vs KOCSAMF vs MAINCSAMF vs JNJCSAMF vs MRKCSAMF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.